مجله علوم پزشکی صدرا

بررسی اثر دریافت رسوراتول و کوئرستین در سرطان کولون

نوع مقاله : مقاله مروری

نویسندگان

پروین اخلاص پور 1
فاطمه نظری رباطی 2
سجاد طزرجی 1

1 دانشجوی کارشناسی ارشد رشته تغذیه، گروه تغذیه، دانشکده علوم تغذیه و مواد غذایی، دانشگاه علوم پزشکی تبریز، ایران

2 دانشجوی ام پی اچ، مرکز تحقیقات اجتماعی بهداشت، مرکز بهداشت شهری کرمان، خیابان شفا، کرمان، ایران

https://doi.org/10.30476/smsj.2021.84071.1074
چکیده
مقدمه: سرطان یکی از شایع ترین بیماری ها در جهان است. در جهان یک مرگ از هر 8 مرگ به دلیل سرطان رخ می دهد. سرطان سومین عامل مرگ در ایران است. سرطان کولون چهارمین علت مرگ در جهان می باشد و سالانه 2/1 میلیون نفر مبتلا به این سرطان تشیخص داده می شوند.
روش‌ها: روش گردآوری اطلاعات از طریق مقالات مروری و اورجینال بوده است.
یافته‌ها: حدود 8 درصد از کل مرگ و میرها مربوط به سرطان کولون می باشد.
نتیجه ­گیری: سرطان کولون در ایران در طی سه دهه اخیر افزایش چشم گیری داشته است و طبق گزارش سالیانه موسسه ثبت ملی سرطان ایران، در حال حاضر از لحاظ شیوع دومین سرطان رایج در ایران می باشد شیوع سرطان کولون در ایران 8 نفر از هر 100000 نفر می باشد. تخمین زده می شود که  هر سال در کشور 3641 مورد جدید سرطان اتفاق می افتد و سالانه 2262 نفر در اثر سرطان کولون جان خود را از دست می دهند.شیوع این سرطان در جمعیت ایرانی 22 درصد می باشد.
واژگان کلیدی: سرطان، کولون، شیوع

کلیدواژه‌ها

سرطان
کولون
شیوع
بدخیمی‌ها
رسوراتول
کوئرستین
  1. Núñez‐Sánchez MA, González‐Sarrías A, Romo‐Vaquero M, García‐Villalba R, Selma MV, Tomás‐Barberán FA, et al. Dietary phenolics against colorectal cancer—From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs. Molecular nutrition & food research. 2015;59(7):1274-91.
  2. Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer epidemiology. 2016;41:88-95.
  3. Yazdizadeh B, Jarrahi A, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev. 2005;6(2):130-4.
  4. Shadi Kolahdoozan MD M, Alireza Sadjadi MD M, Radmard AR, Hooman Khademi MD M. Five common cancers in Iran. Archives of Iranian medicine. 2010;13(2):143.
  5. Somi MH, Golzari M, Farhang S, Naghashi S, Abdollahi L. Gastrointestinal cancer incidence in East Azerbaijan, Iran: update on 5 year incidence and trends. Asian Pac J Cancer Prev. 2014;15(9):3945-9.
  6. Pourhoseingholi MA, Fazeli Z, Ashtari S, Bavand-Pour FSF. Mortality trends of gastrointestinal cancers in Iranian population. Gastroenterology and Hepatology from bed to bench. 2013;6.
  7. Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, et al. Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Science translational medicine. 2015;7(298):298ra117-298ra117.
  8. Boughey JC, Hartmann LC, Anderson SS, Degnim AC, Vierkant RA, Reynolds CA, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. Journal of Clinical Oncology. 2010;28(22):3591-6.
  9. Alizadeh AM, Khaniki M, Azizian S, Mohaghgheghi MA, Sadeghizadeh M, Najafi F. Chemoprevention of azoxymethane-initiated colon cancer in rat by using a novel polymeric nanocarrier–curcumin. European journal of pharmacology. 2012;689(1):226-32.
  10. Siddiqui IA, Adhami VM, Ahmad N, Mukhtar H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer. 2010;62(7):883-90.
  11. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Annals of the New York Academy of Sciences. 2011;1215(1):1-8.
  12. Surh Y-J. Cancer chemoprevention with dietary phytochemicals. Nature Reviews Cancer. 2003;3(10):768-80.
  13. Siddiqui IA, Afaq F, Adhami VM, Mukhtar H. Prevention of prostate cancer through custom tailoring of chemopreventive regimen. Chemico-biological interactions. 2008;171(2):122-32.
  14. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. Journal of Clinical Oncology. 2009;27(16):2712-25.
  15. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxidants & redox signaling. 2008;10(3):475-510.
  16. Bode AM, Dong Z. Cancer prevention research—then and now. Nature Reviews Cancer. 2009;9(7):508-16.
  17. Greenwald P. Clinical trials in cancer prevention: current results and perspectives for the future. The Journal of nutrition. 2004;134(12):3507S-12S.
  18. González-Vallinas M, González-Castejón M, Rodríguez-Casado A, de Molina AR. Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutrition reviews. 2013;71(9):585-99.
  19. HWANG JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Annals of the New York Academy of Sciences. 2007;1095(1):441-8.
  20. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clinical Cancer Research. 2002;8(3):893-903.
  21. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prevention Research. 2009;2(5):409-18.
  22. Singh CK, George J, Ahmad N. Resveratrol‐based combinatorial strategies for cancer management. Annals of the New York Academy of Sciences. 2013;1290(1):113-21.
  23. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomedicine & pharmacotherapy. 2002;56(2):84-7.
  24. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, et al. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer management and research. 2009;1:25.
  25. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC cancer. 2010;10(1):238.
  26. Fouad M, Agha A, Al Merzabani M, Shouman S. Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells Calorie restriction is the force to the cytotoxicity. Human & experimental toxicology. 2013;32(10):1067-80.
  27. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicology and applied pharmacology. 2007;224(3):274-83.
  28. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology Biomarkers & Prevention. 2007;16(6):1246-52.
  29. Niles RM, Cook CP, Meadows GG, Fu Y-M, McLaughlin JL, Rankin GO. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. The Journal of nutrition. 2006;136(10):2542-6.
  30. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1β-induced NF-κB-mediated inflammation and apoptosis. Arthritis Research and Therapy. 2009;11(6).
  31. Sughra K, Birbach A, De Martin R, Schmid JA. Interaction of the TNFR-receptor associated factor TRAF1 with I-kappa B kinase-2 and TRAF2 indicates a regulatory function for NF-kappa B signaling. PloS one. 2010;5(9):e12683.
  32. Park E-S, Lim Y, Hong J-T, Yoo H-S, Lee C-K, Pyo M-Y, et al. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascular pharmacology. 2010;53(1):61-7.
  33. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer science. 2010;101(2):488-93.
  34. Tollefsbol TO. Dietary epigenetics in cancer and aging.  Advances in nutrition and cancer: Springer; 2014. p. 257-67.
  35. Hope C, Planutis K, Planutiene M, Moyer MP, Johal KS, Woo J, et al. Low concentrations of resveratrol inhibit Wnt signal throughput in colon‐derived cells: implications for colon cancer prevention. Molecular nutrition & food research. 2008;52(S1):S52-S61.
  36. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer letters. 2008;269(2):315-25.
  37. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicology in vitro. 2006;20(2):187-210.
  38. Van der Woude H, ter Veld MG, Jacobs N, van der Saag PT, Murk AJ, Rietjens IM. The stimulation of cell proliferation by quercetin is mediated by the estrogen receptor. Molecular nutrition & food research. 2005;49(8):763-71.
  39. Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). The Journal of nutrition. 2006;136(11):2715-21.
  40. Cho S-Y, Park S-J, Kwon M-J, Jeong T-S, Bok S-H, Choi W-Y, et al. Quercetin suppresses proinflammatory cytokines production through MAP kinases and NF-κB pathway in lipopolysaccharide-stimulated macrophage. Molecular and cellular biochemistry. 2003;243(1-2):153-60.
  41. Khandelwal AR, Hebert VY, Kleinedler JJ, Rogers LK, Ullevig SL, Asmis R, et al. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. The Journal of nutrition. 2012;142(8):1487-94.
  42. Smith TK, Lund EK, Johnson IT. Inhibition of dimethylhydrazine-induced aberrant crypt foci and induction of apoptosis in rat colon following oral administration of the glucosinolate sinigrin. Carcinogenesis. 1998;19(2):267-73.
  43. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer. 2009;9(3):153-66.
  44. Yang K, Lamprecht SA, Liu Y, Shinozaki H, Fan K, Leung D, et al. Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis. 2000;21(9):1655-60.
  45. Portt L, Norman G, Clapp C, Greenwood M, Greenwood MT. Anti-apoptosis and cell survival: a review. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2011;1813(1):238-59.
  46. Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1, 2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis. 2006;27(5):1038-46.
  47. Schneider Y, Duranton B, Goss F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutrition and cancer. 2001;39(1):102-7.
  48. Volate SR, Davenport DM, Muga SJ, Wargovich MJ. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis. 2005;26(8):1450-6.
  49. Dihal AA, de Boer VC, van der Woude H, Tilburgs C, Bruijntjes JP, Alink GM, et al. Quercetin, but not its glycosidated conjugate rutin, inhibits azoxymethane-induced colorectal carcinogenesis in F344 rats. The Journal of nutrition. 2006;136(11):2862-7.
  50. Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, Du J, et al. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutrition and cancer. 2009;61(4):544-53.
  51. Martinez M, Hope C, Planutis K, Planutiene M, Pontello A, Duarte B, et al., editors. Dietary grape-derived resveratrol for colon cancer prevention. ASCO Annual Meeting Proceedings; 2010.

مجله علوم پزشکی صدرا
دوره 9، شماره 2
فروردین 1400
صفحه 178-200

صفحه اصلی

راهنمای نویسندگان

ارسال مقاله

راهنمای داوران

تماس با ما